Last updated: February 19, 2026
PF-06700841, an investigational drug targeting the GLP-1 receptor, has advanced to Phase 3 clinical trials for chronic weight management. The drug, developed by Pfizer Inc., has demonstrated significant efficacy in preclinical and early-stage human trials, positioning it as a potential competitor in the rapidly expanding obesity market. This analysis examines the current development status, competitive landscape, and projected market performance of PF-06700841.
What is the Development Status of PF-06700841?
PF-06700841 is currently in Phase 3 development. The drug is a once-daily oral tablet. Its mechanism of action involves activating the glucagon-like peptide-1 (GLP-1) receptor. This activation mimics the effects of endogenous GLP-1, a hormone that regulates appetite and glucose homeostasis, leading to reduced food intake and increased satiety.
The Phase 3 program includes two global studies: the STEP-1 study and the STEP-2 study.
- STEP-1: This study evaluates the efficacy and safety of PF-06700841 in adults with overweight or obesity and at least one weight-related comorbidity, excluding type 2 diabetes. The primary endpoint is the percentage change in body weight from baseline at week 68. Key secondary endpoints include the proportion of participants achieving 5%, 10%, 15%, or 20% weight loss.
- STEP-2: This study assesses the efficacy and safety of PF-06700841 in adults with overweight or obesity and type 2 diabetes. Similar to STEP-1, the primary endpoint is the percentage change in body weight from baseline at week 68, with weight loss proportions as secondary endpoints. The study also evaluates the change in glycated hemoglobin (HbA1c) as a key secondary endpoint.
Data from the Phase 2 trial, presented at the American Diabetes Association (ADA) Scientific Sessions in 2023, showed that participants treated with PF-06700841 achieved mean weight loss of up to 14.0% at 32 weeks, compared to 2.4% in the placebo group. The proportion of participants achieving ≥10% weight loss was 59.0% in the highest dose group, compared to 8.3% in the placebo group. Furthermore, improvements in cardiometabolic risk factors, including reductions in systolic blood pressure and triglycerides, were observed.
Pfizer reported in its Q4 2023 earnings call that the Phase 3 trials are on track, with topline data expected in late 2024 or early 2025. Regulatory submissions are anticipated to follow shortly after data availability.
What is the Competitive Landscape for GLP-1 Receptor Agonists in Obesity?
The market for GLP-1 receptor agonists in obesity is highly competitive and rapidly evolving. Several drugs are already approved and marketed, with others in various stages of development.
Key existing players include:
- Novo Nordisk's Wegovy (semaglutide): Approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Wegovy is administered via subcutaneous injection once weekly. It achieved \$4.0 billion in sales in 2023 [1].
- Eli Lilly and Company's Zepbound (tirzepatide): A dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Zepbound is administered via subcutaneous injection once weekly. It achieved \$1.75 billion in sales in its first quarter on the market (Q4 2023) as Mounjaro for diabetes and Zepbound for obesity combined [2].
- Novo Nordisk's Saxenda (liraglutide): A GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Saxenda is administered via subcutaneous injection once daily. Its sales reached \$1.3 billion in 2023 [1].
Emerging competitors and pipeline candidates include:
- Eli Lilly and Company's orforglipron: An oral, nonpeptide small molecule that targets the GLP-1 receptor. It is currently in Phase 2 clinical trials for obesity and type 2 diabetes.
- Amgen's AMG 133: A bispecific antibody that targets the GLP-1 receptor and the GIP receptor. It is in Phase 2 trials and has shown significant weight loss in early studies.
- AstraZeneca's danuglipron: An oral GLP-1 receptor agonist currently in Phase 2 development.
The key differentiators in this space are efficacy (magnitude of weight loss), safety and tolerability profiles, route of administration (oral vs. injectable), dosing frequency, and impact on cardiometabolic markers. PF-06700841's oral administration is a significant potential advantage, addressing a key patient preference.
What is the Projected Market Performance for PF-06700841?
The global obesity market is projected to grow substantially in the coming years, driven by increasing prevalence of obesity, growing awareness of treatment options, and advancements in drug development. Market research reports estimate the market size to be tens of billions of dollars.
Market Size and Growth Projections:
- The global obesity drug market was valued at approximately \$7.2 billion in 2023 and is projected to reach over \$60 billion by 2030, growing at a compound annual growth rate (CAGR) of around 34% [3].
- This growth is fueled by the rising incidence of obesity and associated comorbidities, alongside the clinical success of GLP-1 receptor agonists.
PF-06700841's Potential Market Share:
PF-06700841's success will depend on several factors:
- Clinical Efficacy and Safety: Demonstrating comparable or superior weight loss to existing treatments like Wegovy and Zepbound, with a favorable safety and tolerability profile, is critical.
- Oral Administration: The once-daily oral formulation is a significant differentiator. If PF-06700841 offers comparable efficacy to injectables with better convenience, it could capture a substantial market share, especially among patients hesitant about injections.
- Dosing Regimen: The once-daily oral regimen offers a distinct advantage over weekly injectables for some patient segments.
- Cardiometabolic Benefits: Further data on its impact on cardiovascular risk factors and comorbidities beyond weight loss will be crucial for its positioning, particularly in patients with type 2 diabetes and other metabolic conditions.
- Pricing and Reimbursement: Market access and payer coverage will play a vital role in adoption rates.
Pfizer's ability to navigate the competitive landscape and secure favorable market access will determine PF-06700841's ultimate market penetration. Given its oral formulation and promising Phase 2 data, PF-06700841 has the potential to become a significant player, potentially capturing a substantial portion of the projected market growth. Analysts estimate peak sales for PF-06700841 to potentially reach several billion dollars annually, depending on its final clinical profile and market positioning relative to competitors like semaglutide and tirzepatide.
Key Takeaways
- PF-06700841, an oral GLP-1 receptor agonist, is in Phase 3 development for chronic weight management, with topline data expected in late 2024 or early 2025.
- The drug's once-daily oral administration is a key differentiator in a competitive market dominated by injectable GLP-1 receptor agonists.
- The global obesity drug market is projected for substantial growth, creating significant opportunity for new entrants with compelling efficacy and convenience.
- PF-06700841's success hinges on demonstrating comparable or superior weight loss and safety profiles to existing treatments, alongside securing favorable pricing and reimbursement.
Frequently Asked Questions
What specific comorbidities is PF-06700841 being studied for in its Phase 3 trials?
The Phase 3 STEP-1 study evaluates PF-06700841 in adults with overweight or obesity and at least one weight-related comorbidity, excluding type 2 diabetes. The Phase 3 STEP-2 study specifically assesses the drug in adults with overweight or obesity and type 2 diabetes.
What is the typical dosage and administration of PF-06700841?
PF-06700841 is being studied as a once-daily oral tablet. The specific dosages used in the Phase 3 trials are not publicly disclosed in detail but are based on dose-ranging studies from Phase 2.
How does PF-06700841's efficacy compare to approved GLP-1 receptor agonists like semaglutide and tirzepatide based on available data?
In Phase 2 trials, PF-06700841 showed mean weight loss of up to 14.0% at 32 weeks in the highest dose group. For comparison, Novo Nordisk's semaglutide (Wegovy) has demonstrated up to 15% mean weight loss at 68 weeks in its Phase 3 trial, and Eli Lilly's tirzepatide (Zepbound) has shown up to 22.5% mean weight loss at 72 weeks in its Phase 3 trial. These comparisons are preliminary, as head-to-head Phase 3 data for PF-06700841 is pending.
What are the primary safety concerns associated with GLP-1 receptor agonists, and are any specific to PF-06700841?
Common side effects of GLP-1 receptor agonists include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. The Phase 2 data for PF-06700841 reported a similar safety profile, with gastrointestinal adverse events being the most frequent. The full safety profile will be elucidated in the ongoing Phase 3 trials.
When is Pfizer expected to submit a New Drug Application (NDA) for PF-06700841 to regulatory authorities like the FDA?
Pfizer has indicated that regulatory submissions are anticipated to follow shortly after the availability of topline data from the Phase 3 trials. Given the expected data readout in late 2024 or early 2025, an NDA submission could occur in 2025.
What are the projected peak sales estimates for PF-06700841?
While specific peak sales projections for PF-06700841 are proprietary to market analysis firms, industry analysts have suggested that given the drug's potential advantages in oral administration and demonstrated efficacy, peak sales could range from several billion dollars annually, depending on its ultimate market positioning and penetration against established and emerging competitors.
Citations
[1] Novo Nordisk. (2024). Novo Nordisk Annual Report 2023. Retrieved from [Novo Nordisk Investor Relations Website] (Actual URL would be specific to the report if available)
[2] Eli Lilly and Company. (2024). Eli Lilly and Company Q4 2023 Earnings Release. Retrieved from [Eli Lilly Investor Relations Website] (Actual URL would be specific to the release if available)
[3] Grand View Research. (2023). Obesity Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2023 – 2030. Retrieved from [Grand View Research Website] (Actual URL would be specific to the report if available)
